Lymphoma Podcasts Lymphoma RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Resminostat maintenance for advanced cutaneous lymphoma: RESMAIN study
Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses the RESMAIN study (NCT0... Author: VJHemOnc Added: 10/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Clinical scoring system for Szary syndrome: results from a retrospective study
An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, discuss... Author: VJHemOnc Added: 10/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2018 Category: Cancer & Oncology Source Type: podcasts

PROCLIPI: registry & establishment of a prognostic index for MF and SS
Establishing a registry and prognostic index for mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), and Szary syndrome, a rare type of CTCL, is important to improve the mana... Author: VJHemOnc Added: 10/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2018 Category: Cancer & Oncology Source Type: podcasts

CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma
CD47 has been found to be present on leukemic stem cells, but not on normal hematopoietic stem cells, offering an opportunity to target the source of the disease. Here, Irving Weissman, MD, of the Sta... Author: VJHemOnc Added: 10/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2018 Category: Cancer & Oncology Source Type: podcasts

CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas
A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and Szary syndrome, the most common types of cu... Author: VJHemOnc Added: 10/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Pathobiology and clinical management of T-cell lymphoma
From the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, Francine Foss, MD, of Yale University School of Medicine, New Haven, CT, discusses the pathology and... Author: VJHemOnc Added: 10/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 1, 2018 Category: Cancer & Oncology Source Type: podcasts

Precision medicine in lymphoma
Precision medicine is improving outcomes, toxicity and disease management in trials and routine clinical practice. Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York City, NY, ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Viral lymphomas: risk factors and treatments
Viruses such Epstein-Barr virus (EBV) and HIV have been aetiologically linked to a significant number of lymphoproliferative diseases. In this roundtable discussion, lead by Catherine Bollard, MBChB, ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Promising therapeutic developments for Hodgkin lymphoma
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses clinical trials testing new drugs on patients with relapsed Hodgkin lymphoma. These agents include brentuximab vedotin and PD-1 blocki... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

MRD in lymphoma
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses ways in which measuring measurable residual disease (MRD) may be ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Brentuximan vedotin for treating Hodgkin Lymphoma
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses encouraging data on patients with Hodgkin lymphoma who received ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Watch and wait: defining the indolent patient group in MCL
While mantle cell lymphoma (MCL) can be an aggressive disease, there is a subgroup of patients whose disease poses low risk, thus treatment may not be required. Here, Simon Rule, MD, from Plymouth Uni... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Challenges in diagnosing and treating CTCL
With cutaneous T-cell lymphoma (CTCL) being a rare disease with an incredibly high prevalence, Pierluigi Porcu, MD, from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the challenges of CTCL... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells in CLL: the current landscape
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind.... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

A risk-adapted treatment approach for mantle cell lymphoma
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Simon Rule, MD, from Plymouth University, Plymouth, UK, outlines the current standards of care for both you... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts